Title:
N-BENZYL-N-ARYLSULFONAMIDE DERIVATIVE AND PREPARATION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/151687
Kind Code:
A1
Abstract:
Provided is an N-benzyl-N-arylsulfonamide derivative, which is an N-benzyl-N-arylsulfonamide compound represented by a general formula (I), or a pharmaceutically acceptable salt or solvate thereof. The N-benzyl-N-arylsulfonamide derivative is obtained by condensing a substituted nitrobenzene with a nitrogen-containing five- or six-membered aliphatic heterocycle (ring B), then reducing the nitro group into an amino group, followed by reductive amination, and sulfamidation; or obtained by subjecting a substituted nitrobenzene to nitro group reduction, then reductive amination, and sulfamidation, followed by condensing with a nitrogen-containing five- or six-membered aliphatic heterocycle (ring B). Experiments showed that the N-benzyl-N-arylsulfonamide derivative of the present invention can specifically bind to and inhibit or reduce the activity of a potassium channel Kv1.3, and can be used to treat an autoimmune disease caused by abnormal activation of the potassium channel Kv1.3 in human or animals. Also provided are a medicament and a pharmaceutical composition comprising the N-benzyl-N-arylsulfonamide derivative.
Inventors:
WANG XIAOLU (CN)
HU YONGZHOU (CN)
YE QING (CN)
HU XIUAI (CN)
HU YONGZHOU (CN)
YE QING (CN)
HU XIUAI (CN)
Application Number:
PCT/CN2020/073367
Publication Date:
July 30, 2020
Filing Date:
January 21, 2020
Export Citation:
Assignee:
HANGZHOU YIRUI PHARMACEUTICAL TECH CO LTD (CN)
International Classes:
C07D295/185; A61K31/402; A61K31/44; A61K31/4409; A61K31/445; A61K31/45; A61K31/451; A61K31/495; A61K31/496; A61K31/505; A61K31/5375; A61P3/04; A61P3/10; A61P19/02; A61P37/00; C07D207/14; C07D211/44; C07D211/54; C07D211/58; C07D211/74; C07D211/88; C07D213/42; C07D231/12; C07D233/64; C07D239/10; C07D239/26; C07D241/08; C07D277/28; C07D295/135; C07D295/195; C07D295/26; C07D307/52
Domestic Patent References:
| WO2010023445A1 | 2010-03-04 | |||
| WO2010023445A1 | 2010-03-04 | |||
| WO2004026823A1 | 2004-04-01 | |||
| WO2010130638A1 | 2010-11-18 |
Foreign References:
| CN109651297A | 2019-04-19 | |||
| CN101389622A | 2009-03-18 |
Other References:
TOLDI G. ET AL., IMMUNOL RES., vol. 64, no. 2, 2016, pages 627 - 631
KAZAMA L, J PHYSIOL SCI., vol. 65, no. 1, 2015, pages 25 - 35
MING HU ET AL., JOURNAL OF IMMUNOLOGY, vol. 26, no. 4, 2010, pages 356 - 361
BEETON ET AL., PNAS, vol. 103, no. 46, 2006, pages 17414 - 17418
KOSHY ET AL., JBIOL CHEM, vol. 289, no. 18, 2014, pages 12623 - 32
CHANDYNORTON, CURR OPIN CHEN BIOL, vol. 38, 2017, pages 97 - 107
ZHAO, TOXINS (BASEL, vol. 7, 2015, pages 1749 - 1764
CHANDYNORTON, CURR OPIN CHEM BIOL, vol. 38, 2017, pages 97 - 107
CAHALANCHANDY, IMMUNOL REV, vol. 231, 2009, pages 59 - 87
WULFF ET AL., J CLIN INVEST, vol. 111, 2003, pages 1703 - 1713
GOCKE ET AL., J IMMUNOL, vol. 188, 2012, pages 5877 - 5886
VALVERDE ET AL., J BONE MINER RES, vol. 19, 2004, pages 155 - 164
HYODO ET AL., AM J PHYSIAL RENAL PHYSIOL, vol. 299, 2010, pages F1258 - 69
AZAM ET AL., J INVEST DERMATAL, vol. 127, no. 6, 2007, pages 1419 - 1427
KUN CLU-RAYCHAUDHURI ET AL., J ANTOIMMUN, vol. 55, 2014, pages 63 - 72
TARCH ET AL.: "PLoS ONE", vol. 12, 13 August 2018, CIRCASSIA, pages: 1 - 19
SCHROEDER ET AL., J BIOMOL SCREEN, vol. 8, no. 1, 2003, pages 50 - 64
GRISSMER ET AL., MOLECULAR PHARMACOLOGY, vol. 45, 1994, pages 1227 - 1234
See also references of EP 3915978A4
KAZAMA L, J PHYSIOL SCI., vol. 65, no. 1, 2015, pages 25 - 35
MING HU ET AL., JOURNAL OF IMMUNOLOGY, vol. 26, no. 4, 2010, pages 356 - 361
BEETON ET AL., PNAS, vol. 103, no. 46, 2006, pages 17414 - 17418
KOSHY ET AL., JBIOL CHEM, vol. 289, no. 18, 2014, pages 12623 - 32
CHANDYNORTON, CURR OPIN CHEN BIOL, vol. 38, 2017, pages 97 - 107
ZHAO, TOXINS (BASEL, vol. 7, 2015, pages 1749 - 1764
CHANDYNORTON, CURR OPIN CHEM BIOL, vol. 38, 2017, pages 97 - 107
CAHALANCHANDY, IMMUNOL REV, vol. 231, 2009, pages 59 - 87
WULFF ET AL., J CLIN INVEST, vol. 111, 2003, pages 1703 - 1713
GOCKE ET AL., J IMMUNOL, vol. 188, 2012, pages 5877 - 5886
VALVERDE ET AL., J BONE MINER RES, vol. 19, 2004, pages 155 - 164
HYODO ET AL., AM J PHYSIAL RENAL PHYSIOL, vol. 299, 2010, pages F1258 - 69
AZAM ET AL., J INVEST DERMATAL, vol. 127, no. 6, 2007, pages 1419 - 1427
KUN CLU-RAYCHAUDHURI ET AL., J ANTOIMMUN, vol. 55, 2014, pages 63 - 72
TARCH ET AL.: "PLoS ONE", vol. 12, 13 August 2018, CIRCASSIA, pages: 1 - 19
SCHROEDER ET AL., J BIOMOL SCREEN, vol. 8, no. 1, 2003, pages 50 - 64
GRISSMER ET AL., MOLECULAR PHARMACOLOGY, vol. 45, 1994, pages 1227 - 1234
See also references of EP 3915978A4
Attorney, Agent or Firm:
SHANGCHENG & PARTNERS (CN)
Download PDF: